Brands Capitalize on Creative with Advances in the Ad-Lib.io Platform
12.7.2022 16:00:00 EEST | Business Wire | Press release
Ad-Lib.io, a Smartly.io company and a leading next-generation Creative Management Platform (CMP), announced today the release of the next generation of Personalize™, Ad-Lib.io’s award-winning cookieless platform for creative management, media alignment and creative intelligence all in one place. Personalize 2.0 delivers breakthrough capabilities to accelerate and scale campaign activation while ensuring brand governance and improved campaign addressability cross-channel.
As a result of these advances, advertisers are experiencing a range of ROAS benefits, including:
- 28% reduction in time required to link media and creative strategies in a single digital workspace,
- 4x faster campaign builds with on-brand assets, published and approved automatically,
- 85% fewer clicks to build personalized variants for every audience in their media plan, and
- Up to a week’s advance notice prior to the onset of campaign fatigue, thanks to AI-driven modeling, along with the creative data insights to tune performance at the variant level.
“Scaling campaigns significantly while comfortably reducing production time has been simply delightful,” said Barbara Piras, Group Head of Digital Marketing at TUI Group. “Adding Ad-Lib.io’s technology to our marketing workflow has opened a new world of creative possibilities I’m excited to explore in the future.”
“Our hyperlocal marketing strategy has been instrumental to our success, and Ad-Lib.io is a key partner in helping us scale our reach and creative effectiveness in record time,” said Dean Weaving, Director of Brand Media Operations at Deliveroo. “Their platform has brought our creative and media teams together at a high level of collaboration and coordination, time and time again. We look forward to continuing our work, leveraging their platform, to bring the same relevant, on-target advertising to a multitude of highly differentiated localities.”
“According to a recent WBR Insights survey, only 10% of advertisers felt that their creative and media teams were aligned. This disconnect leads to a number of inefficiencies and sub-optimal results, and it is a core challenge addressed by our platform,” said Oli Marlow Thomas, Ad-Lib.io Founder. “Our goal is to transform the creative production process into one that is easier, faster, more collaborative, data-advised and better aligned to media strategies.”
With Personalize 2.0, advertisers can now execute multi-market activations across channels in fewer steps, integrate with leading media platforms to instantly pull in target audiences and publish approved creatives while reducing the risk of creative rejection. Advertisers can also build targeted creative campaigns and test and learn strategies at scale in minutes, across display, video and social. AI can be leveraged at every step along the way, from asset cropping for quick and easy image editing across channels and formats, to fatigue alerts to prevent premature decline in campaign performance. Best of all, in-line performance reporting reduces the campaign optimization effort to just a few clicks.
Personalize 2.0 is immediately available. Click here for more information on Ad-Lib.io and the Smartly.io family of creative effectiveness capabilities.
About Ad-lib.io
Ad-Lib.io, a Smartly.io company, provides the leading next-generation Creative Management Platform for marketers at the world’s largest brands to enable them to scale their digital creative. Ad-Lib.io connects creative and media workflows using intelligent automation, making it easy and fast to produce and optimize relevant ad creative across all digital channels. These ads are 60% more cost-efficient to produce, according to Ad-LIb.io’s customers, including TUI, Estee Lauder, IG, Pizza Hut and other global brands.. Recently acquired by Smartly.io, Ad-Lib.io was founded by former Google executives who understood the need to close the wide gap between creative concepts and digital media execution.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005295/en/
Contact information
Dina Magdovitz
smartly.io@pancomm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 15:05:00 EEST | Press release
Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,” said David Weinreich, Global Head of R&D, Merck. “With enpatoran, we aim to target the underlying drivers of lupus and redefine how to approach the disease by understanding both visible skin manifestations and systemic activity.” Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor designed to modulate pathways central to lupus-related inflammatio
The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 15:00:00 EEST | Press release
The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i
Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 15:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are: Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of Michael Kors’ strongest performance periods. Titan of Europe: Ash Cummings, Ecommerce Fraud Prevention Manager, Gymshark A
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release
CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
